Recent therapeutic advances with programmed cell death protein 1 (PD-1)-targeted immunotherapy (e.g., pembrolizumab, nivolumab, and camrelizumab) have shown promising results in phase II and/or phase III studies of advanced HCC [6–10]. Here, PDCD1 is linked to hepatocellular carcinoma.